Key regions: Brazil, India, Australia, United States, United Kingdom
Antiviral drugs have become increasingly important in the treatment of viral infections worldwide. In Iraq, the market for antiviral drugs is also growing steadily.
Customer preferences: Iraqi consumers are becoming more aware of the importance of antiviral drugs in treating viral infections. They are increasingly seeking out these drugs to treat a variety of illnesses, including influenza, hepatitis, and HIV. Additionally, with the recent outbreak of COVID-19, demand for antiviral drugs has increased significantly.
Trends in the market: The antiviral drugs market in Iraq is expected to continue growing in the coming years. This growth is being driven by several factors, including increasing awareness of antiviral drugs, rising incidence of viral infections, and the development of new and more effective antiviral drugs. Additionally, the ongoing COVID-19 pandemic has led to a surge in demand for antiviral drugs in Iraq and around the world.
Local special circumstances: Iraq faces several unique challenges in the antiviral drugs market. One of the biggest challenges is the country's limited healthcare infrastructure, which can make it difficult for patients to access the drugs they need. Additionally, Iraq has a large population of refugees and internally displaced persons, many of whom lack access to basic healthcare services. These factors can make it difficult for antiviral drug manufacturers to reach their target markets in Iraq.
Underlying macroeconomic factors: Iraq's economy has been impacted by political instability and conflict in recent years, which has led to a challenging business environment for companies operating in the country. However, the government has taken steps to improve the investment climate and attract foreign investment, which could help to boost the antiviral drugs market in the coming years. Additionally, Iraq's young and growing population could provide a significant market opportunity for antiviral drug manufacturers in the long term.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
